RE:RE:Phase 3 Data Presentation at Kidney Week 2020 ...You tell me! I just gather the information where and when I can find it. It's up to you to push the pencil.
But ...
What it tells me is ... don't prejudge a Goodman drug deal too early when you don't know what other indications may arise. Any deal is a good deal if you don't overpay, no matter how small it seems.
Looks like a new indication is close at hand based on the data presented (previous article).
Gotta like it !!!!!
------
ONTREAL, June 26, 2019 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for Ibsrela™ (tenapanor) has been accepted for review by Health Canada for the treatment of irritable bowel syndrome with constipation (IBS-C). Knight and Ardelyx Inc. (NASDAQ: ARDX) entered into a license agreement in March 2018 granting Knight the exclusive right to commercialize tenapanor in Canada.
Tenapanor is an oral, first-in-class small molecule treatment under review by the FDA for the treatment of irritable bowel syndrome with constipation (IBS-C) and is being evaluated in a second Phase 3 program for the treatment of hyperphosphatemia in patients with end-stage renal disease (“ESRD”) on dialysis.